Rania Abdel-Latif

Dr. Rania Abdel-Latif


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
RARania Abdel-Latif
Rania Abdel-Latif
Moustafa FathyMoustafa Fathy
Moustafa Fathy
HAHend Ali Anwar
Hend Ali Anwar
MNMuhammad Naseem
Muhammad Naseem
Thomas DandekarThomas Dandekar
Thomas Dandekar
Eman M. OthmanEman M. Othman
Eman M. Othman
Cisplatin is a commonly used chemotherapeutic agent; however, its potential side effects, including gonadotoxicity and infertility, are a critical problem. Oxidative stress has been implicated in the pathogenesis of cisplatin-induced testicular dysfunction. We investigated whether kinetin use at different concentrations could alleviate gonadal injury associated with cisplatin treatment, with an exploration of the involvement of its antioxidant capacity. Kinetin was administered in different doses of 0.25, 0.5, and 1 mg/kg, alone or along with cisplatin for 10 days. Cisplatin toxicity was induced via a single IP dose of 7 mg/kg on day four. In a dose-dependent manner, concomitant administration of kinetin with cisplatin significantly restored testicular oxidative stress parameters, corrected the distorted sperm quality parameters and histopathological changes, enhanced levels of serum testosterone and testicular StAR protein expression, as well as reduced the up-regulation of testicular TNF-α, IL-1β, Il-6, and caspase-3, caused by cisplatin. It is worth noting that the testicular protective effect of the highest kinetin dose was comparable/more potent and significantly higher than the effects of vitamin C and the lowest kinetin dose, respectively. Overall, these data indicate that kinetin may offer a promising approach for alleviating cisplatin-induced reproductive toxicity and organ damage, via ameliorating oxidative stress and reducing inflammation and apoptosis.

21 October 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Mohamed MorsyMohamed Morsy
Mohamed Morsy
RARania Abdel-Latif
Rania Abdel-Latif
SHSara Mohammed Naguib Abdel Hafez
Sara Mohammed Naguib Abdel Hafez
Mahmoud KandeelMahmoud Kandeel
Mahmoud Kandeel
SASeham A. Abdel-Gaber
Seham A. Abdel-Gaber
Methotrexate (MTX) is an effective chemotherapeutic agent against a wide range of tumors and autoimmune diseases; however, hepatotoxicity limits its clinical use. Oxidative stress and inflammation have been implicated in the pathogenesis of MTX-induced hepatotoxicity. Paeonol is a natural phenolic compound reported for its antioxidant and anti-inflammatory properties. The current study aimed to investigate the protective effect of paeonol against MTX-induced hepatotoxicity in rats and various mechanisms that underlie this postulated effect. Paeonol was administered orally in a dose of 100 mg/kg, alone or along with MTX, for 10 days. Hepatotoxicity was induced via a single intraperitoneal dose of MTX (20 mg/kg) on day 5 of the experiment. Concomitant administration of paeonol with MTX significantly ameliorated distorted hepatic function and histological structure, restored hepatic oxidative stress parameters (MDA, NO, and SOD), and combated inflammatory response (iNOS and TNF-α). Additionally, paeonol enhanced cell proliferation and survival, evidenced by upregulating the proliferating cell nuclear antigen (PCNA) and suppressing apoptosis and the disposition of collagen fibers in rat livers treated with MTX. Importantly, paeonol upregulated the drug efflux transporters, namely P-glycoprotein (P-gp) and the multidrug resistance-associated protein 2 (Mrp-2) in MTX-treated rats. In conclusion, paeonol offered a potent protective effect against MTX-induced hepatotoxicity through suppressing oxidative stress, inflammation, fibrosis, and apoptosis pathways, along with P-gp and Mrp-2 upregulation.

14 September 2022 in Life Sciences
Verified
Journal Article
Closed access
Moustafa FathyMoustafa Fathy
Moustafa Fathy
RARania Abdel-Latif
Rania Abdel-Latif
YAYasmeen M. Abdelgwad
Yasmeen M. Abdelgwad
OAOthman Ali
Othman Ali
AAAbdel-Razik Abdel-Razik
Abdel-Razik Abdel-Razik
Eman M. OthmanEman M. Othman
Eman M. Othman

5 August 2025 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
DBDebalina Bose
Debalina Bose
AOAdetayo Olorunlana
Adetayo Olorunlana
RARania Abdel-Latif
Rania Abdel-Latif
Ademola C. FamurewaAdemola C. Famurewa
Ademola C. Famurewa
Eman M. OthmanEman M. Othman
Eman M. Othman
Virgin coconut oil (VCO) has emerged as a functional food oil with considerable health benefits and wide applications in the food, pharmaceutical, and cosmetic industries due to its resident bioactive compounds, including lauric acid (LA). LA is the most abundant saturated medium-chain fatty acid in VCO and has been associated with several pharmacological activities. The literatures show the pharmacological effects of VCO and LA on chronic pathologies, infectious diseases, and metabolic disorders. A robust body of evidence shows that LA and other phenolic compounds are responsible for the VCO protection against toxicities and pharmacological efficacies. This review elucidates the anticancer mechanisms of VCO/LA and their modulation of the chemotherapy-induced side effect toxicity. VCO, LA, and their nanomaterial/encapsulated derivatives promote ROS generation, antiproliferation, apoptosis, cell cycle arrest, the inhibition of metastasis, and the modulation of cancer-related signaling pathways for cancer cell death in vivo and in vitro. VCO mitigates oxidative inflammation and apoptosis to block the underlying mechanisms of the side effect toxicity of chemotherapy. However, the possible beneficial effect of LA on the toxicity of chemotherapy is currently unknown. The available evidence emphasizes the anticancer effect and mechanism of VCO and LA, and the VCO potential to combat adverse side effects of chemotherapy. Thus, VCO and LA are potential adjuvant therapeutic agents in the management of various cancers. Nevertheless, future studies should be targeted at elucidating cancer-related molecular mechanisms to bridge the gap in knowledge.

28 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
SGShahin Gavanji
Shahin Gavanji
ABAzizollah Bakhtari
Azizollah Bakhtari
RARania Abdel-Latif
Rania Abdel-Latif
Elena BencúrováElena Bencúrová
Elena Bencúrová
Eman M. OthmanEman M. Othman
Eman M. Othman
Diabetes mellitus is a global health issue that necessitates the development of novel therapeutic approaches. Today numerous experimental methods have been used and set up to evaluate novel drugs with antidiabetic effects. In addition, several research studies have been done to induce diabetes under in vitro and in vivo conditions, but only a small number of these efforts are currently in a usable stage. This review aims to provide useful guidance for researchers who seek to evaluate the antidiabetic potential of drugs, agents, or new medications using the standard methods published by authorities and academics worldwide organizations and research centers. In this review, we collected 132 relevant articles from prominent databases such as PubMed, ScienceDirect, Scopus and others to summarize in vitro and in vivo experimental validation of antidiabetic treatment from 1943 to present.